Literature DB >> 21592795

Variation of serum creatine kinase (CK) levels and prevalence of persistent hyperCKemia in a Norwegian normal population. The Tromsø Study.

Hallvard Lilleng1, Karin Abeler, Stein H Johnsen, Eva Stensland, Sissel Løseth, Rolf Jorde, Yngve Figenschau, Sigurd Lindal, Tom Wilsgaard, Svein I Bekkelund.   

Abstract

In this cross-sectional study we assessed the prevalence of hyperCKemia, defined as persistent CK values ≥210 U/L in women, ≥400 U/L in men <50 years and ≥280 U/L in men ≥50 years (reference values according to the Nordic Reference Interval Project). Blood samples were obtained from 12,828 participants in the 6th survey of The Tromsø Study. We identified 686 (5.3%) individuals with incidentally elevated CK. After a standardized control test, 169 persons (1.3%) had persistent hyperCKemia, i.e. 69.9% normalization. Use of statins or other causes of hyperCKemia were detected in 78 individuals (46.2%), giving a prevalence of "idiopathic hyperCKemia" of 0.71%. CK variation was highest in younger men and in females between 60 and 69 years. This study has identified persistent hyperCKemia in 1.3% of the normal population, and demonstrates the importance of performing controlled CK analyses, also in those with identified risk factors.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21592795     DOI: 10.1016/j.nmd.2011.04.007

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  6 in total

Review 1.  Approach to asymptomatic creatine kinase elevation.

Authors:  Siamak Moghadam-Kia; Chester V Oddis; Rohit Aggarwal
Journal:  Cleve Clin J Med       Date:  2016-01       Impact factor: 2.321

2.  Creatine kinase is associated with reduced inflammation in a general population: The Tromsø study.

Authors:  Svein Ivar Bekkelund; Stein Harald Johnsen
Journal:  PLoS One       Date:  2018-05-29       Impact factor: 3.240

Review 3.  Real-World Safety of CFTR Modulators in the Treatment of Cystic Fibrosis: A Systematic Review.

Authors:  Renée V E Dagenais; Victoria C H Su; Bradley S Quon
Journal:  J Clin Med       Date:  2020-12-23       Impact factor: 4.241

4.  Characterization of Creatine Kinase Levels in Tofacitinib-Treated Patients with Ulcerative Colitis: Results from Clinical Trials.

Authors:  Remo Panaccione; John D Isaacs; Lea Ann Chen; Wenjin Wang; Amy Marren; Kenneth Kwok; Lisy Wang; Gary Chan; Chinyu Su
Journal:  Dig Dis Sci       Date:  2020-08-20       Impact factor: 3.199

5.  Clinical features of Guillain-Barré syndrome patients with elevated serum creatine kinase levels.

Authors:  Takafumi Hosokawa; Hideto Nakajima; Taiki Sawai; Yoshitsugu Nakamura; Eri Sano; Akihiro Tsukahara; Kiichi Unoda; Shimon Ishida; Sadaki Sakane; Fumiharu Kimura; Shigeki Arawaka
Journal:  BMC Neurol       Date:  2020-05-27       Impact factor: 2.474

6.  Population-Wide Duchenne Muscular Dystrophy Carrier Detection by CK and Molecular Testing.

Authors:  Shuai Han; Hong Xu; Jinxian Zheng; Junhui Sun; Xue Feng; Yue Wang; Wen Ye; Qing Ke; Yanwei Ren; Shulie Yao; Songying Zhang; Jianfen Chen; Robert C Griggs; Zhengyan Zhao; Ming Qi; Michele A Gatheridge
Journal:  Biomed Res Int       Date:  2020-09-27       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.